Hamlet BioPharma Investor Relations Material
Latest events
Investor Update
Hamlet BioPharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Hamlet BioPharma
Access all reports
Hamlet Pharma AB, a pharmaceutical company, engages in the research and development of cancer drugs. The company's lead product candidate is a patented drug that combines the active ingredient Bisantrene-Guanidinylpenicillamine in a galenic form suitable for oral administration. Its BAR treatment is administered through small pills that slowly release the active ingredient into the upper part of the gastrointestinal tract. The company is headquartered in Malmö, Sweden.
Latest articles
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
Ticker symbol
HAMLET
Country
🇸🇪 Sweden